Edition:
United States

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

557.45INR
28 Apr 2017
Change (% chg)

Rs-4.25 (-0.76%)
Prev Close
Rs561.70
Open
Rs561.95
Day's High
Rs561.95
Day's Low
Rs555.00
Volume
865,584
Avg. Vol
1,161,471
52-wk High
Rs621.25
52-wk Low
Rs457.45

CIPL.NS

Chart for CIPL.NS

About

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered... (more)

Overall

Beta: 0.49
Market Cap(Mil.): Rs451,915.59
Shares Outstanding(Mil.): 804.55
Dividend: 2.00
Yield (%): 0.36

Financials

  CIPL.NS Industry Sector
P/E (TTM): 45.44 29.18 30.12
EPS (TTM): 12.36 -- --
ROI: -- 13.76 13.28
ROE: -- 14.71 14.44

BRIEF-Cipla U.S. arm signs worldwide licensing deal with MEDRx

* Medrx is eligible to receive up to USD 30 million cumulatively through upfront and developmental, regulatory, and commercial milestones payments

Apr 06 2017

BRIEF-Medrx signs drug development and sale contract with Cipla USA Inc

* Says the company enters into a license contract with an India-based pharma Cipla Ltd's wholly owned US-based unit Cipla USA Inc, on development and sale of MRX-4TZT, transdermal patch for the treatment of spastic paralysis

Apr 06 2017

BRIEF-Cipla launches Hepatitis B vaccine in India

* Says Cipla launches Hepatitis B vaccine in India Source text - (http://bit.ly/2lUwkV6) Further company coverage:

Feb 17 2017

BRIEF-Cipla Ltd Dec-qtr consol profit up about 44 pct

* Consol net profit in Dec quarter last year was 2.61 billion rupees as per Ind-AS; consol net sales was 30.70 billion rupees

Feb 08 2017

India's Cipla Q3 profit up 43.7 pct, tops estimates

MUMBAI, Feb 8 Indian drugmaker Cipla Ltd reported a 43.7 percent jump in third-quarter net profit, beating analysts' expectations.

Feb 08 2017

UPDATE 1-India's Cipla Q2 profit falls as Europe, emerging markets suffer

MUMBAI, Nov 9 Cipla Ltd, India's fifth-largest drugmaker by sales, on Wednesday reported a 35 percent fall in quarterly profit, missing analysts' estimates, mainly due to lower sales in the emerging markets and Europe.

Nov 09 2016

India's Cipla Q2 profit falls 35 pct

MUMBAI, Nov 9 Cipla Ltd, India's fifth-largest drugmaker by sales, on Wednesday reported a 35 percent fall in quarterly profit, missing analysts' estimates.

Nov 09 2016

BRIEF-Cipla Sept qtr consol profit falls

* Consensus forecast for Sept quarter consol net profit was 3.92 billion rupees

Nov 09 2016

More From Around the Web

Earnings vs. Estimates